Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells

European Journal of Pharmacology

Volumn 398, Issue 2, 2000, Pages 177-183

  Winter, Stephan ^a   Weller, Michael ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

3 Aminobenzamide; Glioma; Nitrosoureas; Poly(ADP ribose) polymerase

Indexed keywords

3 AMINOBENZAMIDE; CAMPTOTHECIN; CARMUSTINE; CYTARABINE; DNA BINDING PROTEIN; DOXORUBICIN; LOMUSTINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMUSTINE; NITROSOUREA; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE; ZINC FINGER PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

BENZAMIDES; BINDING SITES; CARMUSTINE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; G2 PHASE; GLIOMA; HUMANS; LOMUSTINE; METHYLNITROSOUREA; MITOSIS; NIMUSTINE; NITROSOUREA COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR CELLS, CULTURED;

EID: 0034674392     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00326-5     Document Type: Article

References (18)

1. Agarwal M.L., Agarwal A., Taylor W.R., Wang Z.Q., Wagner E.F., Stark G.R. Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase. Oncogene. 15:1997;1035-1041.
2. Borbé R., Rieger J., Weller M. The failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status. Cancer Chemother. Pharmacol. 44:1999;217-227.
3. Chatterjee S., Cheng M.F., Trivedi D., Petzold S.J., Berger N.A. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun. 1:1989;389-394.
4. Cleaver J.E., Morgan W.F. Poly(ADP-ribose) polymerase: a perplexing participant in cellular responses to DNA damage. Mutat. Res. 257:1991;1-18.
5. Ding R., Smulson M. Depletion of nuclear poly(ADP-ribose) polymerase by antisense RNA expression: influences on genomic stability, chromatin organization, and carcinogen cytotoxicity. Cancer Res. 54:1994;4627-4634.
6. Ding R., Pommier Y., Kang V.H., Smulson M. Depletion of poly(ADP-ribose) polymerase by antisense RNA expression results in a delay in DNA strand break rejoining. J. Biol. Chem. 267:1992;12804-12812.
7. Kaufmann S.H., Desnoyers S., Ottaviano Y., Davidson N.E., Poirier G.G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53:1993;3976-3985.
8. Leist M., Single B., Künstle G., Volbracht C., Hentze H., Nicotera P. Apoptosis in the absence of poly(ADP-ribose) polymerase. Biochem. Biophys. Res. Commun. 233:1997;518-522.
9. Ménissier de Murcia J., Niedergang C., Trucco C., Ricoul M., Dutrillaux B., Mark M., Oliver F.J., Masson M., Dierich A., LeMeur M., Walztinger C., Chambon P., De Murcia G. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. U. S. A. 94:1997;7303-7307.
10. Schreiber V., Hunting D., Trucco C., Gowans B., Grunwald D., De Murcia G., Ménissier de Murcia J. A dominant-negative mutant of poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4753-4757.
11. Wang Z.Q., Stingl L., Morrison C., Jantsch M., Los M., Schulze-Osthoff K., Wagner E.F. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev. 11:1997;2347-2358.
12. Wang X., Ohnishi K., Takahashi A., Ohnishi T. Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation. Oncogene. 17:1998;2819-2825.
13. 6-alkylguanine-DNA alkyltransferase activity. Br. J. Cancer. 74:1996;1030-1036.
14. Weller M., Rieger J., Grimmel C., Van Meir E.G., De Tribolet N., Krajewski S., Reed J.C., von Deimling A., Dichgans J. Predicting chemoresistence in human malignant glioma cells: the role of molecular genetic analyses. Int. J. Cancer. 79:1998;640-644.
15. Whitacre C.M., Hashimoto H., Tsai M.L., Chatterjee S., Berger S.J., Berger N.A. Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res. 55:1995;3697-3701.
16. Winter S., Weller M. Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L expression. J. Pharmacol. Exp. Ther. 286:1998;1374-1382.
17. Wright S.C., Wie Q.S., Kinder D.H., Larrick J.W. Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide-deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation. J. Exp. Med. 183:1996;463-471.
18. Zhang J., Dawson V.L., Dawson T.M., Snyder S.H. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science. 263:1994;687-689.